These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6104976)

  • 1. Metabolic and cardiovascular side effects of the beta 2-adrenoceptor agonists salbutamol and rimiterol.
    Phillips PJ; Vedig AE; Jones PL; Chapman MG; Collins M; Edwards JB; Smeaton TC; Duncan BM
    Br J Clin Pharmacol; 1980 May; 9(5):483-91. PubMed ID: 6104976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man.
    Marlin GE; Turner P
    Br J Clin Pharmacol; 1975 Feb; 2(1):41-8. PubMed ID: 10940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relative potencies and beta2-selectivities of intravenous rimiterol, salbutamol and isoprenaline in asthmatic patients.
    Marlin GE; Turner P
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):158-69. PubMed ID: 240780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous treatment with rimiterol and salbutamol in asthma.
    Marlin GE; Turner P
    Br Med J; 1975 Jun; 2(5973):715-9. PubMed ID: 1139193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between the bronchodilator and cardiovascular effects of inhaling 0.5 mg. rimiterol ('Pulmadil') and 0.2 mg. salbutamol.
    Bianco S; Kamburoff PL; Prime FJ
    Curr Med Res Opin; 1975; 3(1):30-5. PubMed ID: 1116382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further studies of rimiterol and salbutamol administered by intermittent positive-pressure ventilation, and an important observation on the technique of using the Bennett ventilator.
    Paterson IC; Willey RF; Shotter MV; Crompton GK
    Br J Clin Pharmacol; 1977 Oct; 4(5):605-9. PubMed ID: 20919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of rimiterol and salbutamol by inhalation at high and low dose in asthmatic patients.
    Muittari A
    Respiration; 1978; 35(3):165-72. PubMed ID: 25466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular and biochemical responses to nebulised salbutamol in normal subjects.
    Smith SR; Ryder C; Kendall MJ; Holder R
    Br J Clin Pharmacol; 1984 Oct; 18(4):641-4. PubMed ID: 6487508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of tolerance to oral salbutamol in the third trimester of pregnancy: a study of circulatory and metabolic effects.
    Wager J; Fredholm BB; Lunell NO; Persson B
    Br J Clin Pharmacol; 1981 Oct; 12(4):489-95. PubMed ID: 6271156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a need to treat hypokalaemia associated with intravenous salbutamol infusion?
    Chua S; Razvi K; Wong MT; Tay R; Arulkumaran S
    J Obstet Gynaecol Res; 1997 Aug; 23(4):381-7. PubMed ID: 9311181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Actions of the sympathomimetic bronchodilator, rimiterol (R798), on the cardiovascular, respiratory and skeletal muscle systems of the anaesthetized cat.
    Bowman WC; Rodger IW
    Br J Pharmacol; 1972 Aug; 45(4):574-83. PubMed ID: 5085231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative potencies and beta2-adrenoreceptor selectivities of rimiterol and salbutamol aerosols.
    Marlin GE; Hartnett BJ; Berend N
    Br J Clin Pharmacol; 1977 Feb; 4(1):77-9. PubMed ID: 14660
    [No Abstract]   [Full Text] [Related]  

  • 13. Response to rimiterol and salbutamol aerosols administered by intermittent positive-pressure ventilation.
    Cooke NJ; Kerr JA; Willey RF; Hoare MV; Grant IW; Cromptom GK
    Br Med J; 1974 May; 2(5913):250-2. PubMed ID: 4597119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intravenous injection of rimiterol in asthma.
    Tarala RA; Martyn V; Paterson JW
    Br J Clin Pharmacol; 1981 Sep; 12(3):333-40. PubMed ID: 6117302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The metabolic actions of intravenous salbutamol and aminophylline singly and in combination.
    Jenkins CR; Marlin GE
    Br J Clin Pharmacol; 1981 Feb; 11(2):197-201. PubMed ID: 7011349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of beta-adrenoceptor subtype mediating the metabolic actions of salbutamol.
    Berend N; Marlin GE
    Br J Clin Pharmacol; 1978 Mar; 5(3):207-11. PubMed ID: 207295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects.
    Bennett JA; Tattersfield AE
    Thorax; 1997 May; 52(5):458-64. PubMed ID: 9176539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypokalaemia and other non-bronchial effects of inhaled fenoterol and salbutamol: a placebo-controlled dose-response study in healthy volunteers.
    Scheinin M; Koulu M; Laurikainen E; Allonen H
    Br J Clin Pharmacol; 1987 Nov; 24(5):645-53. PubMed ID: 2829953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic and hormonal effects of preferential beta 1 and beta 2-adrenoceptor stimulation in man.
    Tantucci C; Santeusanio F; Beschi M; Castellano M; Sorbini C; Grassi V
    J Endocrinol Invest; 1988 Apr; 11(4):279-87. PubMed ID: 2842389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic and cardiovascular effects of salbutamol in atopic subjects with and without asthma.
    Kallenbach J; Joffe BI; Zwi S; Seftel HC
    Scand J Respir Dis; 1979 Feb; 60(1):44-8. PubMed ID: 220703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.